OBT076 not checked

Oxford BioTherapeutics Ltd · MEN1309

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Solid Tumor
Main trialPhase 1
“The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the…”In the company’s words, NCT04064359 on ClinicalTrials.gov
Other names
MEN1309

Other drugs for Solid Tumor

All 2439 drugs for Solid Tumor

Coming up1

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 31 Dec 2027 Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow OBT076

Following is part of Solo: you see every change to OBT076 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in